Literature DB >> 32308890

Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods.

Xi Yang1, Yan Gong2,3, Nida Waheed4, Keith March5, Jiang Bian1, William R Hogan1, Yonghui Wu1.   

Abstract

Cardiotoxicity related to cancer therapies has become a serious issue, diminishing cancer treatment outcomes and quality of life. Early detection of cancer patients at risk for cardiotoxicity before cardiotoxic treatments and providing preventive measures are potential solutions to improve cancer patients' quality of life. This study focuses on predicting the development of heart failure in cancer patients after cancer diagnoses using historical electronic health record (EHR) data. We examined four machine learning algorithms using 143,199 cancer patients from the University of Florida Health (UF Health) Integrated Data Repository (IDR). We identified a total number of 1,958 qualified cases and matched them to 15,488 controls by gender, age, race, and major cancer type. Two feature encoding strategies were compared to encode variables as machine learning features. The gradient boosting (GB) based model achieved the best AUC score of 0.9077 (with a sensitivity of 0.8520 and a specificity of 0.8138), outperforming other machine learning methods. We also looked into the subgroup of cancer patients with exposure to chemotherapy drugs and observed a lower specificity score (0.7089). The experimental results show that machine learning methods are able to capture clinical factors that are known to be associated with heart failure and that it is feasible to use machine learning methods to identify cancer patients at risk for cancer therapy-related heart failure. ©2019 AMIA - All rights reserved.

Entities:  

Year:  2020        PMID: 32308890      PMCID: PMC7153053     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  23 in total

1.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

2.  Prediction modeling using EHR data: challenges, strategies, and a comparison of machine learning approaches.

Authors:  Jionglin Wu; Jason Roy; Walter F Stewart
Journal:  Med Care       Date:  2010-06       Impact factor: 2.983

3.  Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology.

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Carlo G Tocchetti
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

4.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Authors:  Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

5.  PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations.

Authors:  Joshua C Denny; Marylyn D Ritchie; Melissa A Basford; Jill M Pulley; Lisa Bastarache; Kristin Brown-Gentry; Deede Wang; Dan R Masys; Dan M Roden; Dana C Crawford
Journal:  Bioinformatics       Date:  2010-03-24       Impact factor: 6.937

Review 6.  Pharmacogenetics of anthracyclines.

Authors:  Judit C Sági; Nóra Kutszegi; Andrea Kelemen; Lili E Fodor; András Gézsi; Gábor T Kovács; Dániel J Erdélyi; Csaba Szalai; Ágnes F Semsei
Journal:  Pharmacogenomics       Date:  2016-06-08       Impact factor: 2.533

7.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

Review 8.  Cardiotoxicity in anthracycline therapy: Prevention strategies.

Authors:  Margarida Cruz; Joana Duarte-Rodrigues; Manuel Campelo
Journal:  Rev Port Cardiol       Date:  2016-05-31       Impact factor: 1.374

Review 9.  Global Cancer Incidence and Mortality Rates and Trends--An Update.

Authors:  Lindsey A Torre; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-14       Impact factor: 4.254

Review 10.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.

Authors:  Edward T H Yeh; Courtney L Bickford
Journal:  J Am Coll Cardiol       Date:  2009-06-16       Impact factor: 24.094

View more
  1 in total

1.  An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline.

Authors:  Hsiang-Chun Lee; Jhih-Yuan Shih; Wei-Ting Chang; Chung-Feng Liu; Yin-Hsun Feng; Chia-Te Liao; Jhi-Joung Wang; Zhih-Cherng Chen
Journal:  Arch Toxicol       Date:  2022-07-25       Impact factor: 6.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.